References
- 1. Kuźnik A, Październiok-Holewa A, Jewula P, Kuźnik N. Bisphosphonates-much more than only drugs for bone diseases. Eur J Pharmacol. 2020;866:172773
- 2. Giger EV, Castagner B, Leroux JC. Biomedical applications of bisphosphonates. J Control Release 2013;167:175–188.
- 3. Jung J, Park JS, Righesso L, et al. Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro. Clin Oral Investig. 2018;22:2527-2534.
- 4. Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci. 2015;11:319-324.
- 5. Di Fede O, Panzarella V, Mauceri R, et al. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. Biomed Res Int. 2018;2018:2684924. Published 2018 Sep 16.
- 6. Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing?. Injury. 2016;47 Suppl 1:S65-S68.
- 7. Giger EV, Castagner B, Leroux JC. Biomedical applications of bisphosphonates. J Control Release 2013; 167: 175–188.
- 8. Savino S, Toscano A, Purgatorio R, et al. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis. Eur J Med Chem. 2018;158:184-200.
- 9. De Colli M, Tortorella P, Agamennone M, et al. Bisphosfonate matrix metalloproteinase inhibitors for the treatment of periodontitis: An in vitro study. Int J Mol Med. 2018;42:651-657.
- 10. Akram Z, Abduljabbar T, Kellesarian SV, Abu Hassan MI, Javed F, Vohra F. Efficacy of bisphosphonate as an adjunct to nonsurgical periodontal therapy in the management of periodontal disease: a systematic review. Br J Clin Pharmacol. 2017;83:444-454.
- 11. Wayama MT, Yoshimura H, Ohba S, et al. Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats. J Endod. 2015;41:2002-2007.
- 12. Silva RAB, Sousa-Pereira AP, Lucisano MP, et al. Alendronate inhibits osteocyte apoptosis and inflammation via IL-6, inhibiting bone resorption in periapical lesions of ovariectomized rats. Int Endod J. 2020;53:84-96.
- 13. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393:364-376.
- 14. Weitzmann MN. Bone and the Immune System. Toxicol Pathol. 2017;45:911-924.
- 15. Tobeiha M, Moghadasian MH, Amin N, Jafarnejad S. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. Biomed Res Int. 2020;2020:6910312. Published 2020 Feb 19.
- 16. Kenkre JS, Bassett J. The bone remodelling cycle. Ann Clin Biochem. 2018;55(3):308-327.
- 17. Holstein SA. A patent review of bisphosphonates in treating bone disease. Expert Opin Ther Pat. 2019;29:315-325.
- 18. Yu Z, Surface LE, Park CY, et al. Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing bisphosphonates. Elife. 2018;7:e36620. Published 2018 May 10.
- 19. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85:1052-1062.
- 20. Dayanand P, Sandhyavenu H, Dayanand S, Martinez J, Rangaswami J. Role of Bisphosphonates in Vascular calcification and Bone Metabolism: A Clinical Summary. Curr Cardiol Rev. 2018;14:192-199.
- 21. Zameer S, Najmi AK, Vohora D, Akhtar M. Bisphosphonates: Future perspective for neurological disorders. Pharmacol Rep. 2018;70:900-907.
- 22. Noronha Oliveira M, Schunemann WVH, Mathew MT, et al. Can degradation products released from dental implants affect peri-implant tissues?. J Periodontal Res. 2018;53:1-11.
- 23. Pellegrini G, Francetti L, Barbaro B, Del Fabbro M. Novel surfaces and osseointegration in implant dentistry. J Investig Clin Dent. 2018;9:e12349.
- 24. Turri A, Rossetti PH, Canullo L, et al. Prevalence of peri-implantitis in medically compromised patients and smokers: a systematic review. Int J Oral Maxillofac Implants. 2016;31:111-118.
- 25. Meyle J, Casado P, Fourmousis I, Kumar P, Quirynen M, Salvi GE. General genetic and acquired risk factors, and prevalence of peri-implant diseases - Consensus report of working group 1. Int Dent J. 2019;69 Suppl 2:3-6.
- 26. French D, Grandin HM, Ofec R. Retrospective cohort study of 4,591 dental implants: Analysis of risk indicators for bone loss and prevalence of peri-implant mucositis and peri-implantitis. J Periodontol. 2019;90:691-700.
- 27. Ata-Ali J, Ata-Ali F, Peñarrocha-Oltra D, Galindo- Moreno P. What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res. 2016;27:e38-e46
- 28. de-Freitas NR, Lima LB, de-Moura MB, Veloso- Guedes CC, Simamoto-Júnior PC, de-Magalhães D. Bisphosphonate treatment and dental implants: A systematic review. Med Oral Patol Oral Cir Bucal. 2016;21:e644-e651. Published 2016 Sep 1.
- 29. Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiødt M, Klinge B. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis. Clin Oral Implants Res. 2018;29 Suppl 18:54-92.
- 30. Khoury F, Hidajat H. Extensive Autogenous Bone Augmentation and Implantation in Patients Under Bisphosphonate Treatment: A 15-Case Series. Int J Periodontics Restorative Dent. 2016;36:9-18
- 31. Kellesarian SV, Subhi ALHarthi S, Saleh Binshabaib M, Javed F. Effect of local zoledronate delivery on osseointegration: a systematic review of preclinical studies. Acta Odontol Scand. 2017;75:530-541.
- 32. He Y, Bao W, Wu XD, Huang W, Chen H, Li Z. Effects of Systemic or Local Administration of Zoledronate on Implant Osseointegration: A Preclinical Meta-Analysis. Biomed Res Int. 2019;2019:9541485. Published 2019 Sep 22.
- 33. Liapatas S, Nakou M, Rontogianni D. Inflammatory infiltrate of chronic periradicular lesions: an immunohistochemical study. Int Endod J. 2003.
- 34. França TRT, Ramos-Perez FMM, Pontual ADA, Castro JFL, Bonan PRF, Perez DEDC. Effects of Zoledronic Acid in Experimental Periapical Lesions in Rats: An Imaging and Histological Analysis. Braz Dent J. 2017;28:566-572.
- 35. Wayama MT, Yoshimura H, Ohba S, et al. Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats. J Endod. 2015;41:2002-2007.
- 36. Lertpimonchai A, Rattanasiri S, Arj-Ong Vallibhakara S, Attia J, Thakkinstian A. The association between oral hygiene and periodontitis: a systematic review and meta-analysis. Int Dent J. 2017;67:332-343.
- 37. Martinho FC, Leite FR, Nóbrega LM, et al. Comparison of Fusobacterium nucleatum and Porphyromonas gingivalis Lipopolysaccharides Clinically Isolated from Root Canal Infection in the Induction of Pro-Inflammatory Cytokines Secretion. Braz Dent J. 2016;27:202-207.
- 38. Frencken JE, Sharma P, Stenhouse L, Green D, Laverty D, Dietrich T. Global epidemiology of dental caries and severe periodontitis - a comprehensive review. J Clin Periodontol. 2017;44 Suppl 18:S94-S105.
- 39. De Colli M, Tortorella P, Agamennone M, et al. Bisphosfonate matrix metalloproteinase inhibitors for the treatment of periodontitis: An in vitro study. Int J Mol Med. 2018;42:651-657.
- 40. Buduneli E, Vardar-Şengül S, Buduneli N, Atilla G, Wahlgren J, Sorsa T. Matrix Metalloproteinases, Tissue Inhibitor of Matrix Metalloproteinase-1, and Laminin- 5 γ2 Chain Immunolocalization in Gingival Tissue of Endotoxin-Induced Periodontitis in Rats: Effects of Low-Dose Doxycycline and Alendronate. J Periodontol. 2007;78:127-134.
- 41. Soundia A, Hadaya D, Esfandi N, et al. Zoledronate Impairs Socket Healing after Extraction of Teeth with Experimental Periodontitis. J Dent Res. 2018;97:312-320.
- 42. Kanoriya D, Pradeep AR, Singhal S, Garg V, Guruprasad CN. Synergistic Approach Using Platelet-Rich Fibrin and 1% Alendronate for Intrabony Defect Treatment in Chronic Periodontitis: A Randomized Clinical Trial. J Periodontol. 2016;87:1427-1435.
- 43. Kanoriya D, Pradeep AR, Garg V, Singhal S. Mandibular Degree II Furcation Defects Treatment With Platelet- Rich Fibrin and 1% Alendronate Gel Combination: A Randomized Controlled Clinical Trial. J Periodontol. 2017;88:250-258.
- 44. Camacho-Alonso F, Davia-Peña RS, Vilaplana-Vivo C, Tudela-Mulero MR, Merino JJ, Martínez-Beneyto Y. Synergistic effect of photodynamic therapy and alendronate on alveolar bone loss in rats with ligature-induced periodontitis. J Periodontal Res. 2018;53:306-314.
- 45. Sharma A, Raman A, Pradeep AR. Role of 1% alendronate gel as adjunct to mechanical therapy in the treatment of chronic periodontitis among smokers. J Appl Oral Sci. 2017;25:243-249.
- 46. Hiltunen AK, Skogman ME, Rosenqvist K, et al. Bioactive glass combined with bisphosphonates provides protection against biofilms formed by the periodontal pathogen Aggregatibacter actinomycetemcomitans. Int J Pharm. 2016;501:211-220.
- 47. Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: A literature review. J oral Biosci. 2019;61:99–104. * Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication- related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017;10:CD012432. Published 2017 Oct 6.
- 48. Khan A, Morrison A, Cheung A, Hashem W, Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int. 2016;27:853-859.
- 49. Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177-187.
- 50. Holtmann H, Lommen J, Kübler NR, et al. Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials. J Int Med Res. 2018;46:4277-4296.
- 51. Nicolatou-Galitis O, Kouri M, Papadopoulou E, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019;27:383-394.
- 52. Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo. 2017;69:9-15.
- 53. Mânea HC, Urechescu HC, Balica NC, et al. Bisphosphonates- induced osteonecrosis of the jaw - epidemiological, clinical and histopathological aspects. Rom J Morphol Embryol. 2018;59:825-831.
- 54. Ruggiero SL. Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw. Oral Maxillofac Surg Clin North Am. 2015;27:479-487.
- 55. Ruggiero S, Dodson T, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 2014;72:1938–56.
- 56. Dodson TB. Risk Factors.Oral Maxillofac Surg Clin North Am. 2015; 27: 509-516.
- 57. Di Fede O, Panzarella V, Mauceri R, et al. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. Biomed Res Int. 2018;2018:2684924. Published 2018 Sep 16.
- 58. Mücke T, Krestan CR, Mitchell DA, Kirschke JS, Wutzl A. Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review. Semin Musculoskelet Radiol. 2016;20:305-314.
- 59. Kos M, Junka A, Smutnicka D, Bartoszewicz M, Kurzynowski T, Gluza K. Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2013;71:1010–6.
- 60. Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci. 2015;11:319-324.